Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
32.67
Nov 19 • 3:59 PM ET Dollar change-0.06 Percentage change(-0.18%)
Aftermarket Close
32.67
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
300.00M
Enterprise Value
331.90M
Income
-3.02M
Sales
111.91M
Book/sh
0.83
Cash/sh
1.83
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
108
IPO
Apr 07, 1994
P/E
-
Forward P/E
58.34
PEG
-
P/S
2.68
P/B
39.14
P/C
17.87
P/FCF
41.15
EV/EBITDA
22.64
EV/Sales
2.97
Quick Ratio
2.03
Current Ratio
2.24
Debt/Eq
6.35
LT Debt/Eq
6.30
Option/Short
No / Yes
EPS (ttm)
-0.35
EPS next Y
0.56
EPS next Q
0.14
EPS this Y
250.00%
EPS next Y
646.67%
EPS next 5Y
-
EPS past 3/5Y
-63.11% -41.80%
Sales past 3/5Y
31.03% 45.92%
EPS Y/Y TTM
91.93%
Sales Y/Y TTM
9.82%
EPS Q/Q
95.43%
Sales Q/Q
7.96%
Insider Own
46.90%
Insider Trans
0.00%
Inst Own
31.35%
Inst Trans
12.20%
ROA
-3.36%
ROE
-34.85%
ROIC
-5.39%
Gross Margin
90.73%
Oper. Margin
10.88%
Profit Margin
-2.69%
SMA20
0.81%
SMA50
-3.34%
SMA200
24.63%
Trades
Shs Outstand
9.18M
Shs Float
4.88M
52W High
35.52 -8.02%
52W Low
16.05 103.60%
Volatility
1.97% 2.75%
ATR (14)
0.78
RSI (14)
47.66
Beta
1.19
Rel Volume
0.81
Avg Volume
180.18K
Volume
146,834
Perf Week
0.40%
Perf Month
-0.31%
Perf Quarter
-5.17%
Perf Half Y
38.20%
Perf YTD
39.91%
Perf Year
71.41%
Perf 3Y
-1.27%
Perf 5Y
4.32%
Perf 10Y
558.67%
Prev Close
32.73
Price
32.67
Change %
-0.18%
Consensus
Hold
Avg. Price Target
$35.00
Implied Upside
+7.1%
Analysts3incl. previous ratings
Rating Distribution2 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 30, 2026Downgrade
HH.C. Wainwright
Buy → Neutral$35+7.1%
Apr 15, 2026Initiated
LLake Street
Buy$32-2.1%
Mar 26, 2025Reiterated
HH.C. Wainwright
Buy$50 → $51+56.1%
Dec 23, 2024Initiated
HH.C. Wainwright
Buy$50+53.0%
May 20, 2022Resumed
CCantor Fitzgerald
Overweight$45 → $40+22.4%
Jun 30, 2021Initiated
CCantor Fitzgerald
Overweight$45+37.7%
Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.
Executive ChairmanMr. Ronald T. Nixon
PresidentMr. Seth D. Yon
Chief Financial OfficerMs. Elizabeth B. Taylor
Chief Operating OfficerMr. Jacob A. Waldrop
Principal Accounting OfficerMs. Ashley M. Mackey